Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43858   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-000075-33
    Sponsor's Protocol Code Number:OMS721-IGA-001
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-05-31
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2018-000075-33
    A.3Full title of the trial
    A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN)

    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)
    A.3.2Name or abbreviated title of the trial where available
    ARTEMIS-IGAN
    A.4.1Sponsor's protocol code numberOMS721-IGA-001
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03608033
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorOmeros Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportOmeros Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSyneos Health LLC
    B.5.2Functional name of contact pointAnita Burroughs
    B.5.3 Address:
    B.5.3.1Street Address1030 Sync Street
    B.5.3.2Town/ cityMorrisville
    B.5.3.3Post codeNC 27560
    B.5.3.4CountryUnited States
    B.5.4Telephone number001919749-7949
    B.5.5Fax number001919749-7949
    B.5.6E-mailanita.burroughs@syneoshealth.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/18/1984
    D.3 Description of the IMP
    D.3.1Product nameNarsoplimab
    D.3.2Product code OMS721
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNarsoplimab
    D.3.9.1CAS number 2108782-45-0
    D.3.9.2Current sponsor codeOMS721
    D.3.9.3Other descriptive nameMASP-2 Antibody, OMS00620646, OMS620646
    D.3.9.4EV Substance CodeSUB194964
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number185
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    IgA nephropathy (IgAN)
    E.1.1.1Medical condition in easily understood language
    Nephritis caused by deposition of antibodies in the kidneys
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10021263
    E.1.2Term IgA nephropathy
    E.1.2System Organ Class 10038359 - Renal and urinary disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of narsoplimab on 24-hour UPE in patients with IgA nephropathy (IgAN) on patients with high baseline proteinuria
    (high-risk proteinuria group; 24-hour urine protein excretion (UPE) in ≥ 2 g/day) assessed at 36 weeks from baseline
    E.2.2Secondary objectives of the trial
    To evaluate the effect of narsoplimab in patients with IgAN on:

    - Renal function as determined by the rate of change in estimated glomerular filtration rate (eGFR) up to 96 weeks from baseline in
    patients with high baseline proteinuria (the high-risk proteinuria group; 24-hour UPE ≥ 2 g/day)
    - Proteinuria assessed by 24-hour UPE at 36 weeks from baseline in the all patients population
    - Renal function as determined by the rate of change in eGFR at up to 96 weeks from baseline in the all-patients population
    - Durability of proteinuria response from 36 weeks in patients with high baseline proteinuria (the high-risk proteinuria group; 24-hour UPE ≥ 2 g/day) and in the all-patients population
    - Change from baseline in log-transformed 24-hour UPE at Week 36 in the all-patients population (24-hour UPE > 1 g/day)

    Refer to protocol for exhaustive list of secondary objectives
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Age 18 years or older at the onset of Screening
    • Biopsy confirmed diagnosis of IgAN within 8 years prior to Screening or Run In Visit 1
    • Documented history of proteinuria of > 1 g/day within 6 months prior to Screening, or uPCR > 0.75 by spot urine at Screening
    • Mean of two proteinuria measurements > 1 g/day at baseline
    • Estimated glomerular filtration rate of ≥ 30 mL/min/1.73 m2 at Screening and baseline
    E.4Principal exclusion criteria
    • Treatment with immunosuppressants (e.g., azathioprine or cyclophosphamide), Chinese Traditional Medicine with
    immunosuppressive function, cytotoxic drugs, or eculizumab within 8 weeks prior to Screening, unless such treatment is given for indications
    other than IgAN
    • Treatment with systemic corticosteroids within 8 weeks prior to Screening
    • Uncontrolled BP, a systolic BP of > 150 mmHg and a diastolic BP of >100 mmHg at rest despite the combination of two or more
    antihypertensives including ACE inhibiters, ARBs, or direct renin inhibitors
    • Female patients who are pregnant, breast feeding, or planning to become pregnant up through 12 weeks after the last dose of study drug,
    including possible retreatments. Males who are planning to father children up through 12 weeks after the last dose of study drug, including possible retreatments.
    • Clinical or biological evidence of Type 1 diabetes mellitus (DM) or poorly controlled DM with hemoglobin A1c > 7.5, or with evidence of
    diabetic nephropathy on biopsy, systemic lupus erythematosus, IgA Vasculitis (Henoch-Schonlein purpura), secondary IgAN, or other renal
    disease, during Screening or Run-In
    • Presence of significant morbidity or other major illness or disease that may confound the interpretation of the clinical trial results or may result in death within 2 years of Screening
    • History of renal transplantation
    • Have a known hypersensitivity to any constituent of the investigational product
    • Rapidly progressive glomerulonephritis, defined as a fall in eGFR of > 30 mL/min/1.73 m2 within 24 weeks or > 15 mL/min/1.73 m2 within
    12 weeks prior to Screening. During the Run-In period a patient will be excluded if they experience a decrease in eGFR of > 15 mL/min/1.73 m2
    from their best eGFR from the beginning of Screening.
    • Significant abnormalities in clinical laboratory values including any of the following at the time of evaluation during Screening and Run-In:
    a. hemoglobin < 9.0 g/dL
    b. platelet count < 100,000 cells/mm3
    c. absolute neutrophil count < 500 cells/mm3
    d. alanine transaminase or aspartate transaminase (AST) > 3.0 × the upper limit of normal (ULN)
    e. serum bilirubin > 2 × ULN
    • History of human immunodeficiency virus (HIV), evidence of immune suppression, active hepatitis C virus (HCV) infection (patients with
    positive anti-HCV antibody but a non-detected HCV RNA PCR can enroll), and/or HBV hepatitis B virus (HBV) infection (patients with positive
    HBsAg are excluded. For patients with isolated positive anti-HBc antibody, HBV DNA test by PCR must be non-detectable to enroll).
    • Diagnosis of a malignancy except for adequately treated and cured basal or squamous cell skin cancer, curatively treated in situ disease, or
    other cancer from which the patient has been disease-free for ≥ 5 years
    • Have received any other investigational drug or device or experimental procedures within 30 days of the Screening Visit (SV) or within 5 times
    the plasma half-life of the administered experimental drug, whichever is longer
    • Treatment with or change in dosing of sodium glucose co-transporter 2 inhibitors (SGLT2i) during Screening and Run-In Periods. However, a
    stable dose regimen established at least 8 weeks prior to screening is acceptable.
    • Treatment with TARPEYO™ (budesonide) or other approved treatments for IgAN within 6 months prior to screening. Treatment with TARPEYO is not allowed during Screening and Run-In Periods.
    • Treatment with Kerendia® (finerenone) within 6 months prior to screening. Treatment with Kerendia is not allowed during Screening and
    Run-In Periods.
    • Initiation of treatment with Filspari™ (sparsentan), a dual Endothelin Angiotensin Receptor Antagonist (dEARA) or similar medication within
    three months prior to screening. A stable dose initiated at minimum 3 months before screening is acceptable and will take the place of
    ACEi/ARB as background therapy
    E.5 End points
    E.5.1Primary end point(s)
    • The primary endpoint of this study is the change from baseline in log-transformed 24-hour UPE in g/day at 36 weeks in patients with high
    baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2 g/day)
    E.5.1.1Timepoint(s) of evaluation of this end point
    36 weeks
    E.5.2Secondary end point(s)
    Key Secondary Endpoints
    • The rate of change in eGFR up to 96 weeks from baseline in patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE
    ≥ 2 g/day)
    • The rate of change in eGFR up to 96 weeks from baseline in the all patients population (24-hour UPE > 1 g/day)
    Other Secondary Endpoints
    • Change from baseline in log-transformed 24-hour UPE at Week 36 in the all patients population. (24-hour UPE > 1 g/day)
    • Time-averaged change from baseline in the log-transformed 24-hour UPE between 36 weeks and 48 weeks in patients with ≥ 2 g/day UPE at
    baseline (high-risk proteinuria group)
    • Time-averaged change from baseline in the log-transformed 24-hour UPE between 36 weeks and 72 weeks in patients with ≥ 2 g/day UPE at
    baseline (high-risk proteinuria group)
    • Time-averaged change from baseline in the log-transformed 24-hour UPE between 36 weeks and 48 weeks in the all-patients population
    • Time-averaged change from baseline in the log-transformed 24-hour UPE between 36 weeks and 72 weeks in the all-patients population
    E.5.2.1Timepoint(s) of evaluation of this end point
    36, 48, and 72 weeks for UPE, and 96 week for the rate of change in eGFR.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Singapore
    Taiwan
    Australia
    Canada
    India
    Korea, Republic of
    Thailand
    Turkey
    United Kingdom
    United States
    Belgium
    Bulgaria
    Czechia
    Germany
    Greece
    Hungary
    Italy
    Lithuania
    Poland
    Slovakia
    Spain
    Sweden
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 410
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 40
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 225
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Applicable local standard of care
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-06-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-10-03
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-01-12
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 13:11:55 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA